GSK Resultados de beneficios anteriores

Pasado controles de criterios 4/6

GSK ha aumentado sus beneficios a una tasa media anual de 0.5%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un descenso de 1.7% anual. Los ingresos han ido disminuyendo a una tasa media de 3.1% al año. La rentabilidad financiera de GSK es de 41.5%, y sus márgenes netos son de 16.2%.

Información clave

0.5%

Tasa de crecimiento de los beneficios

-0.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	14.1%
Tasa de crecimiento de los ingresos	-3.1%
Rentabilidad financiera	41.5%
Margen neto	16.2%
Próxima actualización de resultados	01 May 2024

Actualizaciones de resultados anteriores recientes

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Feb 07

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero GSK. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:GSK Ingresos, gastos y beneficios (GBP Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	30,328	4,928	9,156	5,823
30 Sep 23	29,652	6,078	8,965	5,671
30 Jun 23	29,334	5,373	8,767	5,436
31 Mar 23	29,085	4,455	8,469	5,282
31 Dec 22	29,324	4,461	8,179	5,153
30 Sep 22	29,024	3,387	7,803	4,905
30 Jun 22	27,822	3,505	7,429	4,741
31 Mar 22	26,731	4,013	7,104	4,691
31 Dec 21	24,696	3,316	6,784	4,627
30 Sep 21	26,359	3,567	7,436	4,640
30 Jun 21	28,378	3,934	8,285	4,566
31 Mar 21	30,164	4,983	9,176	4,622
31 Dec 20	24,354	4,873	7,041	4,397
30 Sep 20	34,259	6,371	10,719	4,537
30 Jun 20	34,998	6,679	11,085	4,648
31 Mar 20	35,183	5,380	10,993	4,519
31 Dec 19	33,754	4,645	10,962	4,405
30 Sep 19	33,052	4,561	10,103	4,266
30 Jun 19	31,759	4,427	9,575	4,065
31 Mar 19	31,260	3,904	9,488	3,887
31 Dec 18	30,821	3,623	9,500	3,799
30 Sep 18	30,263	1,862	9,234	3,755
30 Jun 18	30,014	1,656	9,185	3,696
31 Mar 18	30,024	1,035	9,143	3,890
31 Dec 17	30,186	1,532	9,424	3,925
30 Sep 17	30,133	2,335	9,303	3,886
30 Jun 17	29,832	1,931	9,260	3,863
31 Mar 17	29,044	1,676	9,017	3,604
31 Dec 16	27,889	912	8,852	3,550
30 Sep 16	26,589	301	8,553	3,370
30 Jun 16	25,174	31	8,025	3,226
31 Mar 16	24,530	615	8,097	3,163
31 Dec 15	23,923	8,422	9,232	3,560
30 Sep 15	23,823	9,809	7,810	3,218
30 Jun 15	23,342	9,672	7,425	3,227
31 Mar 15	23,015	10,177	7,261	3,258
31 Dec 14	23,006	2,756	8,246	3,450
30 Sep 14	23,726	4,184	7,209	3,333
30 Jun 14	24,590	4,752	7,673	3,359
31 Mar 14	25,647	5,143	7,820	3,478
31 Dec 13	26,505	5,436	8,480	3,923
30 Sep 13	26,401	3,823	7,514	3,430
30 Jun 13	26,418	3,959	7,820	3,543

Ingresos de calidad: GSK tiene un gran one-off loss de £1.7B impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio (16.2%) de GSK son superiores a los del año pasado (15.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de GSK han crecido un 0.5% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de GSK en el último año (10.5%) supera su media de 5 años (0.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de GSK en el último año (10.5%) superó al de la industria Pharmaceuticals 3.8%.

Rentabilidad financiera

Alta ROE: Aunque la rentabilidad financiera (41.49%) de GSK es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

GSK Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

GSK plc to Report Q1, 2024 Results on May 01, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Upcoming dividend of UK£0.14 per share at 4.3% yield

GSK (LON:GSK) Has Announced A Dividend Of £0.14

Gsk plc Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gsk plc Announces Positive Headline Results from Planned Analysis of Part 1 of the Ruby/Engot-En6/Gog3031/Nsgo Phase Iii Trial

GSK plc Announces Positive Preliminary Results from its Phase III Trial Evaluating the Immune Response and Safety of Arexvy

GSK plc Receives Positive CHMP Opinion Recommending Approval of Jemperli (Dostarlimab) Plus Chemotherapy as A New Frontline Treatment for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Update on Zantac (Ranitidine) Litigation

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc to Report Q3, 2023 Results on Nov 01, 2023

Is GSK (LON:GSK) A Risky Investment?

GSK plc Announces Board Changes

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Approves Arexvy for the Prevention of RSV

US Food and Drug Administration Approves GSK Plc's Ojjaara (Momelotinib) for the Treatment of Intermediate or High-Risk Myelofibrosis, Including Primary Myelofibrosis or Secondary Myelofibrosis

GSK Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese Regulator

Gsk plc Announces Nucala Crswnp Submission Accepted in Japan

GSK plc Announces Positive Results from the First-Ever Efficacy Trial of Shingrix in China

GSK plc Announces AREXVY, Respiratory Syncytial Virus Vaccine, Available At All Major US Retail Pharmacies

Upcoming dividend of UK£0.14 per share at 4.4% yield

GSK plc Announced That the US Food and Drug Administration Approved Jemperli (Dostarlimab) in Combination with Carboplatin and Paclitaxe

GSK plc Announces Dividend for Second Quarter of 2023, Payable on 12 October 2023

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta